Recursion Pharmaceuticals just reported Q3 2026 results and the stock slipped 3.9% to US$3.68. The headline is simple: the market focused on another sizeable quarterly loss, while the real story sat in how revenue and the loss line moved together.
Across the quarter, Recursion generated US$18.6 million in sales and recorded a net loss of US$119.0 million. That gap between a modest top line and heavy spending is the main fault line investors are reacting to today. The question now is whether the current one day pullback reflects those fundamentals or leans too much on fear about sustained losses.
Love the science behind Recursion Pharmaceuticals but concerned about heavy quarterly losses against a small revenue base? Compare that profile with companies screening for stronger cash generation and sturdier finances in our list of solid balance sheet and fundamentals stocks (23 results).
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs. Q3 2025): US$18.6 million vs. US$5.2 million (higher quarterly revenue)
- Net Loss (Q3 2026 vs. Q3 2025): US$119.0 million loss vs. US$162.3 million loss (smaller quarterly loss)
- Basic EPS (Q3 2026 vs. Q3 2025): US$0.22 loss per share vs. US$0.36 loss per share (narrower loss per share)
- Products in Phase I (Q3 2026 vs. Q3 2025): 7 programs vs. 5 programs (larger early stage clinical pipeline)
Polyp cuts, durable off-drug responses, and a long cash runway. Ask Charlie what Recursion’s early FAP data really signal.
Recursion Bull Case Tied To Concrete Milestones
The optimistic view hangs on Recursion Pharmaceuticals repeatedly turning its AI engine and dataset into real programs and partner economics that show up in reported numbers.
"The main thing that has to go right is that Recursion Pharmaceuticals continues to turn its efficiency gains, partnerships and early clinical signals from assets like REC‑4881 and REC‑1245 into meaningful, externally validated drug candidates and milestones, despite current revenue pressure and dilution risk."
Q3 results give some backing to that claim. Revenue reached US$18.6 million and the quarterly loss narrowed versus Q3 2025. Since August, Genentech advanced a neuroscience target, Sanofi exercised its first option with a US$10 million milestone, and REC‑4881 plus REC‑1245 produced encouraging clinical data, all pointing to tangible progress against that productivity goal.
One Narrative disagrees with today's price. → See where this Narrative says Recursion Pharmaceuticals should trade.
Recursion Bear Case: Milestones Still Thin Against Cash Burn
Bearish investors argue Recursion Pharmaceuticals could struggle to turn its AI platform and collaborations into enough cash inflow to match heavy spend.
"Despite management cutting pro forma operating expenses by nearly 40% and guiding to cash OpEx of US$375 million in 2026, the combination of a US$0.25 per share quarterly loss and guidance that current cash of about US$557 million funds operations only into early 2028 indicates that any setback in delivering new milestones or advancing assets may force further cost cuts or equity issuance, which could affect future earnings per share."
The Q3 print shows the concern has not gone away. Recursion posted US$18.6 million of revenue against a US$119.0 million loss, plus a fresh US$200 million equity raise. Sanofi’s US$10 million milestone and progress at Genentech validate the model, yet the earnings mix is still heavily dependent on a few events. With the stock down 3.9% on the day and revenue modest versus outlay, the fear that milestones are not broad or frequent enough is only partly addressed, not disproved.
Hunt For Mispriced Cash Engines
Recursion Pharmaceuticals just showed how a single quarter can change how investors view a business. The real opportunity is finding stocks that could be undervalued before the market reassesses them.
- Company 1 - 31% below our estimate - expand workplace retirement access as policy encourages employees into plans that deepen advice and savings relationships.
- Company 2 - 18% below our estimate - ride AI data center demand as high density NAND nodes move more bits into enterprise storage.
- Company 3 - 16% below our estimate - win complex manufacturing programs as regulated customers shift multi year production to a focused, higher margin partner.
Three companies from the same screener. Open all 35 potentially undervalued companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com